Pharm-Olam Insights Blog | Oncology-Hematology Disease

By Ahmed Abufarag, Senior Project Manager
On September 30, 2021

Adaptive Design Considerations for Early Phase Oncology Trials

“Adaptive designs” in clinical research refer to study designs where certain features are left flexible on purpose, so they can...

(6 minute read)

By Ben Manderman, MD MPH
On August 10, 2021

A liquid biopsy is a testing technique where a sample of blood is analysed for cancer cells from a tumour that is circulating in...

(4 minute read)

By Renee Butler
On March 31, 2021

Oncology is a multi-faceted field of study and a popular one. Cancer clinical trials account for more than 19% of the research...

(4 minute read)

By Renee Butler
On March 16, 2021

Cancer research has evolved exponentially over the last two centuries. The first time radiation was used to cure cancer happened...

(4 minute read)

By Renee Butler
On March 9, 2021

Rare oncology is a subset of Oncology that encompasses those cancers with the rarest incidence. They may be a common type like...

(4 minute read)

By Ibett Romero
On March 19, 2020

Pharm-Olam is a mid-sized, global CRO that provides clinical research solutions for rare diseases, oncology, hematology,...

(1 minute read)

By Ryan Michalek
On March 11, 2020

Cohort management is part and parcel of conducting dose-escalation studies, but not all teams effectively manage it. Pharm-Olam...

(5 minute read)